What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian CancerПодробнее

What to Expect When Going on a PARP Inhibitor for Ovarian CancerПодробнее

The Promise of Immunotherapy for Ovarian Cancer | Dana-Farber Cancer InstituteПодробнее

PARP Inhibitors: a Breakthrough in Cancer Therapy?Подробнее

Dana-Farber research presented at the 2018 Society for Gynecologic Oncology annual meetingПодробнее

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian CancerПодробнее

Gynecologic Cancer Education: PARP Inhibitor TherapyПодробнее

Q&A: What About PARP Inhibitors?Подробнее

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer InstituteПодробнее

PARP Inhibitors: a Breakthrough in Cancer Therapy?Подробнее

PARP inhibitors and immunotherapy in ovarian cancer: From research to practiceПодробнее

Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancerПодробнее

PARP Inhibitors for Maintenance Therapy in Ovarian CancerПодробнее

Everything You Want to Know About PARP InhibitorsПодробнее

Center for BRCA & Related Genes 2022 Scientific Symposium | Morning SessionПодробнее

PARP Inhibitors For The Treatment & Prevention Of Hereditary Breast & Ovarian CancerПодробнее

PARP-inhibitors: A New Generation of Cancer DrugsПодробнее

Future Role of PARP Inhibition in BRCA+ Breast CancerПодробнее